Canada Pension Plan Investment Board Sells 233,875 Shares of Edwards Lifesciences Corporation $EW

Key Points

• The Canada Pension Plan Investment Board reduced its stake in Edwards Lifesciences Corporation by 30.7%, selling 233,875 shares and retaining 528,865 shares valued at approximately $38.3 million.
• Several institutional investors, including AQR Capital Management and Brighton Jones LLC, have recently modified their positions in Edwards Lifesciences, indicating significant interest in the stock.
• Analysts have a consensus rating of Moderate Buy for Edwards Lifesciences, with a target price averaging $85.90, following positive earnings reports that surpassed estimates.

Canada Pension Plan Investment Board reduced its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 30.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 528,865 shares of the medical research company's stock after selling 233,875 shares during the quarter. Canada Pension Plan Investment Board owned 0.09% of Edwards Lifesciences worth $38,332,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the period. Brown Advisory Inc. boosted its holdings in Edwards Lifesciences by 7.6% during the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after acquiring an additional 575,699 shares during the period. Deutsche Bank AG boosted its holdings in Edwards Lifesciences by 10.4% during the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after acquiring an additional 652,923 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Edwards Lifesciences by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after acquiring an additional 513,468 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Edwards Lifesciences by 24.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 4,615,163 shares of the medical research company's stock worth $341,661,000 after buying an additional 921,500 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.07 during trading hours on Friday, reaching $80.89. The company had a trading volume of 2,218,583 shares, compared to its average volume of 4,452,792. The business has a fifty day moving average price of $78.71 and a 200-day moving average price of $75.17. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The firm has a market cap of $47.49 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.70 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on EW shares. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Finally, Argus raised Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock valued at $1,698,844 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.